Q-omics provides the consensus-scored DCDC1 profile across patient tissues and cancer cell-line models. DCDC1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DCDC1 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, DCDC1 RNA expression shows 17,578 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, KICH, and KIRP as cancer lineages where DCDC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCDC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCDC1 survival associations across molecular data types. DCDC1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCDC1 RNA expression–survival associations across cancer types. High DCDC1 expression shows unfavorable associations in KICH, LUAD and READ, but favorable associations in UVM, BRCA and SCLC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for DCDC1 RNA expression.
This table summarizes DCDC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DCDC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCDC1 shows lower tumor expression in KICH, THCA, LUAD and LUSC and higher tumor expression in BRCA and BLCA. The KICH box plot shows higher DCDC1 RNA expression in normal versus tumor tissue (log2 FC = −0.801, t-test p < 0.001).
This table shows molecular features associated with DCDC1 in patient tissues and cancer cell lines. In patient samples, DCDC1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, DCDC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
